CAS Number55142-85-3
Synonyms5-[(2-Chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; TICLID; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine; MFCD00661081; 5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; Ticlopidina; 1,2,3,4-tetrahydro-N-<(2-chlorophenyl)methyl>-thieno<3,2-c>pyridine; Ticlopidine; Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidinum; Ticlopidine (INN); 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; EINECS 259-498-5; Ticlopidina [INN-Spanish]
Molecular FormulaC14H14N1Cl1S1
Molecular Weight263.79
Purity98.00%
Density1.3±0.1 g/cm3
Boiling Point367.3±37.0 °C at 760 mmHg
Appearancelight yellow solid
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 55142-85-3 |
| Catalog No. | 2A-9012715 |
| Chinese Name | 噻氯匹啶 |
| Synonyms | 5-[(2-Chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; TICLID; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine; MFCD00661081; 5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; Ticlopidina; 1,2,3,4-tetrahydro-N-<(2-chlorophenyl)methyl>-thieno<3,2-c>pyridine; Ticlopidine; Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidinum; Ticlopidine (INN); 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; EINECS 259-498-5; Ticlopidina [INN-Spanish] |
| Molecular Formula | C14H14N1Cl1S1 |
| Molecular Weight | 263.79 |
| Purity | 98.00 |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 367.3±37.0 °C at 760 mmHg |
| Appearance | light yellow solid |
| Storage Condition | -20℃ |
| Application | Ticlopidine (PCR 5332) is an antithrombotic prodrug that acts as an allosteric non-competitive inhibitor of CD39 with an IC50 of 81.7 µM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 17 |
| HTC | 2934999090 |
| MDL Number | MFCD00661081 |
| SMILES | Clc1ccccc1CN1CCc2sccc2C1 |
| InChI | InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2 |
| InChI Key | PHWBOXQYWZNQIN-UHFFFAOYSA-N |
| MSDS | msds/12715_1_55142_85_3.pdf |
| Use of | Properties Name ticlopidine Synonym More Synonyms Ticlopidine Biological Activity Related Catalog Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Cytochrome P450 Cytochrome P450[1] References [1]. Laura Schäkel, et al. 2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors. Arch Pharm (Weinheim). 2021 Dec;354(12):e2100300. [2]. I.KRASLOVA1, et al. Ticlopidine-Induced Cholestatic Inflammatory Hepatitis: New Insights into Pathogenetic Mechanisms of Drug-Related Hepatotoxicity. [3]. Si-hyung Yang, et al. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. Acta Pharmacol Sin. 2011 Jul;32(7):967-72. [4]. F Piovella, et al. The effect of Ticlopidine on human endothelial cells in culture. Thromb Res. 1984 Feb 1;33(3):323-32. Chemical & Physical Properties Exact Mass 263.053558 PSA 31.48000 Index of Refraction 1.638 InChIKey PHWBOXQYWZNQIN-UHFFFAOYSA-N Storage condition -20℃ Toxicological Information CHEMICAL IDENTIFICATION RTECS NUMBER : CHEMICAL NAME : Thieno(3,2-c)pyridine, 4,5,6,7-tetrahydro-5-((2-chlorophenyl)methyl)- CAS REGISTRY NUMBER : 55142-85-3 LAST UPDATED : DATA ITEMS CITED : MOLECULAR FORMULA : C14-H14-Cl-N-S MOLECULAR WEIGHT : HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : SPECIES OBSERVED : Human - man DOSE/DURATION : TOXIC EFFECTS : Lungs, Thorax, or Respiration - other changes Blood - agranulocytosis Blood - thrombocytopenia REFERENCE : APHRER Annals of Pharmacotherpy. (Harvey Whitney Books Co., POB 42696, Cincinnati, OH 45242) V. 26- 1992- Volume(issue)/page/year: 28,1236,1994 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : SPECIES OBSERVED : Human - woman DOSE/DURATION : TOXIC EFFECTS : Blood - aplastic anemia Blood - changes in bone marrow (not otherwise specified) Nutritional and Gross Metabolic - body temperature increase REFERENCE : IJMDAI Israel Journal of Medical Sciences. (POB 1435, Jerusalem 91013, Israel) V.1- 1965- Volume(issue)/page/year: 31,444,1995 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : SPECIES OBSERVED : Human - man DOSE/DURATION : TOXIC EFFECTS : Gastrointestinal - hypermotility, diarrhea REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,407,1984 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : SPECIES OBSERVED : Human - woman DOSE/DURATION : TOXIC EFFECTS : Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - urine volume decreased Blood - eosinophilia REFERENCE : AJKDDP American Journal of Kidney Diseases. (Grune & Stratton, Inc., Journal Subscription Dept., POB 6280, Duluth, MN 55806) V.1- 1981- Volume(issue)/page/year: 25,934,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : SPECIES OBSERVED : Rodent - rat DOSE/DURATION : TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - pleural thickening Skin and Appendages - hair REFERENCE : NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,295,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - pleural thickening Skin and Appendages - hair REFERENCE : NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,295,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - pleural thickening Skin and Appendages - hair REFERENCE : NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,295,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - pleural thickening Skin and Appendages - hair REFERENCE : NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,295,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - pleural thickening Skin and Appendages - hair REFERENCE : NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,295,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - pleural thickening Skin and Appendages - hair REFERENCE : NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,295,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : SPECIES OBSERVED : Primate - monkey DOSE/DURATION : TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - pleural thickening Skin and Appendages - hair REFERENCE : NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,295,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Primate - monkey DOSE/DURATION : TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - pleural thickening Skin and Appendages - hair REFERENCE : NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,295,1983 Safety Information Hazard Codes C,Xi Risk Phrases R34:Causes burns. WGK Germany 3 HS Code 2934999090 Synthetic Route 2-(2-bromoethyl... 865187-82-2 2-Chlorobenzyla... Ticlopidine 55142-85-3 4,5,6,7-Tetrahy... 54903-50-3 o-Chlorobenzylc... Ticlopidine 55142-85-3 Literature: European Journal of Medicinal Chemistry, , vol. 9, # 5 p. 483 - 486 1-[(2-chlorophe... 128988-10-3 Ticlopidine 55142-85-3 Literature: US4965359 A1, ; Precursor & DownStream Precursor 9 CAS#:865187-82-2 2-(2-bromoethyl... CAS#:89-97-4 2-Chlorobenzylamine CAS#:54903-50-3 4,5,6,7-Tetrahy... CAS#:611-19-8 o-Chlorobenzylc... DownStream 2 CAS#:68559-55-7 4-Oxo Ticlopidine CAS#:83427-51-4 5-[(2-Chlorophe... |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Tibolone | 5630-53-5 | 2A-9012710 |
| Tibric acid | 37087-94-8 | 2A-9012711 |
| Tibrofan | 15686-72-3 | 2A-9012712 |
| Ticarcillin | 34787-01-4 | 2A-9012713 |
| Ticarcillin disodium | 4697-14-7 | 2A-9012714 |
| Ticlopidine hydrochloride | 53885-35-1 | 2A-9012716 |
| Ticolubant | 154413-61-3 | 2A-9012717 |
| Ticrynafen | 40180-04-9 | 2A-9012718 |
| Tienoxolol | 90055-97-3 | 2A-9012719 |
| Tilisolol | 85136-71-6 | 2A-9012720 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS